Millions of Americans now inject weekly doses that quiet the constant mental chatter about food. Cravings fade. Meals shrink. Snack aisles look less tempting. The surge in GLP-1 medications has delivered striking weight loss for many. It has also triggered measurable shifts in what households buy and eat.
Drugmakers Eli Lilly and Novo Nordisk stand as clear winners. Their combined sales from these treatments topped $67 billion last year. Food and beverage companies face the opposite pressure. Projections point to annual industry revenue losses between $30 billion and $55 billion by 2030 to 2034. Consumers on the drugs take in 21% fewer calories and spend 31% less on groceries, according to The Motley Fool.
But the story runs deeper than simple calorie cuts. Households using GLP-1 drugs reduced grocery spending by 5.3% on average within six months. Higher-income households saw an 8% drop. Purchases of ultra-processed foods, savory snacks, sweets and baked goods fell around 10%. Yogurt, meat snacks, nutrition bars and fresh produce gained ground.
Pharma’s Windfall Meets Food’s Reckoning
Eli Lilly reported $36.5 billion in combined sales from Mounjaro and Zepbound in 2025. Novo Nordisk generated $31 billion from Wegovy and Ozempic. That demand propelled Novo to become Denmark’s largest company by market value, equivalent to roughly one-third of the nation’s economic output. Both firms continue to invest heavily in manufacturing expansion and next-generation candidates.
Recent reports show Lilly channeling its cash flow into an aggressive acquisition spree. The company announced roughly $25 billion across 10 deals this year alone. The moves signal confidence that the GLP-1 boom has staying power. Yet supply constraints and competition remain real risks.
On the food side, the pain appears concentrated in traditional snack and indulgence categories. A Brand Finance analysis placed $73 billion of global food brand value at risk. PepsiCo’s Lay’s potato chips carry the heaviest exposure with $6.8 billion of its $15.1 billion brand value vulnerable. The company’s five major snack brands together face $14.1 billion in potential erosion. Doritos, Hershey’s, Cheetos, Kellogg’s and Reese’s also rank high on the list, per Food Dive.
Henry Farr, valuation director at Brand Finance, captured the nuance. “The challenge is not that consumers will stop buying chocolate or crisps altogether, but that millions of everyday consumption decisions could become smaller, less frequent, or shift towards entirely different categories.” Even modest habit changes scale into major commercial consequences at the level of the world’s largest food brands.
General Mills CEO Jeff Harmening told analysts last week that anti-obesity drugs “will have a lasting influence on the food market.” His comment echoed across earnings calls. Nearly three dozen food companies mentioned GLP-1 drugs or weight loss during early 2026 calls. That compares with just five two years earlier.
Restaurants feel it too. Diners on the medications order less, leave plates half full and visit less often. McDonald’s has tested high-protein options including grilled chicken wraps, egg bites and burger bowls without buns. Burger King experimented with smaller “Whopper Bites.” Shake Shack rolled out a “Good Fit” menu emphasizing protein.
Yet not every executive sounds alarmed. PepsiCo CEO Ramon Laguarta said recently his company has not seen a “direct impact.” Mondelēz International assessed the threat and concluded that while portions shrink during use, habits often revert after stopping the drugs. Its modeling suggested a possible 1.5% volume hit by 2035.
The data tells a more complex tale. A Cornell University study found grocery spending shrank 6% in households with at least one GLP-1 user. UK research showed households with users spent £418 less annually on groceries. Gallup data indicates 11% of U.S. adults now take these medications, up from 3% in 2024. Obesity rates have ticked down in tandem.
Consumers describe the change in personal terms. One retired entertainment lawyer in Los Angeles switched to yogurts with 20 grams of protein instead of 13. A Michigan nurse cut his grocery bill 10% to 15%, spent savings on new smaller clothes and now treats chips as a rare indulgence. He eats half his restaurant meals and drinks less alcohol.
These patterns force product reformulation at scale. Companies flood shelves with high-protein, high-fiber versions of old favorites. Protein Doritos. High-protein Kraft Mac & Cheese. Protein Pop-Tarts. Fiber-boosted SunChips. Nestlé launched Vital Pursuit in 2024, its first major new U.S. brand in nearly 30 years. The frozen meals, marketed as compatible with GLP-1 use, feature pizzas with 33 grams of protein and 17 grams of fiber.
“We designed the product for GLP-1 users,” said Federico Sarzi Braga, president of frozen foods at Nestle USA, in The New York Times. “But only 20 percent of that business is coming from a real GLP user,” he added, citing Circana data. The broader weight-management crowd has embraced the line.
Danone introduced an Oikos yogurt drink aimed at muscle retention for drug users. Conagra added “GLP-1 friendly” labels to dozens of Healthy Choice frozen meals. Ferrero bought better-for-you oatmeal brand Purely Elizabeth shortly after acquiring Kellogg. General Mills pushed smaller pack sizes, Honey Nut Cheerios Protein and new granola lines.
The innovation wave extends beyond snacks. Starbucks lets customers add protein cold foam to lattes. WK Kellogg amps up marketing for high-fiber Raisin Bran. Even spice blends gain attention as some users report dulled taste sensations.
Analysts debate duration. Oral GLP-1 pills appear to curb snacking less aggressively than injections, according to Bloomberg Intelligence surveys. Muscle-loss concerns drive demand for protein-rich items. Some users report the return of “food noise” after 9 to 18 months, prompting renewed focus on diet even while continuing medication.
Longer term, the drugs could reshape entire categories. Sales of alcohol, chips, ice cream and sodas have already slipped. Bras in larger sizes sell less. Spending rises on fitness, perfume and premium smaller-portion proteins. Beef consumption drops in volume but shifts toward higher-quality cuts that command better prices.
Pharma companies eye broader consumer plays. Novo Nordisk now talks about a “Consumer Rx” segment. Partnerships with food makers for complementary nutrition products have emerged in markets like India, where lower-cost semaglutide versions recently launched.
The shift rewards agility. Companies that quickly reformulate, resize portions and highlight protein and fiber stand to capture new loyalty. Those clinging to old volume-driven models risk steady erosion. The data already shows clear winners and losers. Drugmakers collect record revenue. Traditional snack giants recalibrate. And millions of consumers quietly eat less, move differently and rethink their relationship with food.
That change looks permanent for many. The food industry must adapt or watch demand drift elsewhere. Pharma’s surge shows no sign of slowing. Its ripple effects will test food executives for years to come.